Besponsa (inotuzumab ozogamicin) is an antibody pharmaceutical. Inotuzumab ozogamicin was first approved as Besponsa on 2017-06-28. It is used to treat precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against B-cell receptor CD22.
|Common Name||Inotuzumab ozogamicin|
|Indication||precursor cell lymphoblastic leukemia-lymphoma|
|Drug Class||Monoclonal antibodies: humanized, tumors as target; antibiotics (Micromonospora strains)|